Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked...
Main Authors: | Cristiano Bortoluzzi, Enrico Bernardi, Giuseppe Camporese, Franco Noventa, Davide Ceccato, Chiara Tonello, Ngoc Vo Hong, Elena Campello, Chiara Simion, Egidio Imbalzano, Pierpaolo Di Micco, Elena Callegari, Paolo Simioni |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/12/10/1657 |
Similar Items
-
Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
by: Enrico Bernardi, et al.
Published: (2022-10-01) -
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01) -
RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01) -
Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01) -
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
by: Kochawan Boonyawat, et al.
Published: (2021-02-01)